| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/02/2023 | 64.2% | Piper Sandler | $40 → $25 | Maintains | Overweight |
| 10/16/2023 | 37.93% | Leerink Partners | → $21 | Initiates Coverage On | → Market Perform |
| 10/02/2023 | 51.07% | Citigroup | $31 → $23 | Maintains | Neutral |
| 10/02/2023 | 195.57% | Jefferies | $47 → $45 | Maintains | Buy |
| 08/21/2023 | 103.61% | Citigroup | $33 → $31 | Maintains | Neutral |
| 08/21/2023 | 110.18% | Baird | $33 → $32 | Maintains | Neutral |
| 08/07/2023 | 307.22% | Barclays | $71 → $62 | Maintains | Overweight |
| 08/04/2023 | 123.32% | TD Cowen | $52 → $34 | Maintains | Outperform |
| 08/04/2023 | 97.04% | Wells Fargo | $40 → $30 | Maintains | Equal-Weight |
| 08/04/2023 | 116.75% | Baird | $38 → $33 | Maintains | Neutral |
| 08/04/2023 | 116.75% | Citigroup | $45 → $33 | Downgrades | Buy → Neutral |
| 06/13/2023 | 228.41% | Craig-Hallum | $74 → $50 | Maintains | Buy |
| 06/05/2023 | 195.57% | Citigroup | $55 → $45 | Maintains | Buy |
| 05/05/2023 | 116.75% | B of A Securities | $45 → $33 | Downgrades | Neutral → Underperform |
| 05/04/2023 | 162.73% | Wells Fargo | $43 → $40 | Maintains | Equal-Weight |
| 05/04/2023 | 149.59% | Baird | $40 → $38 | Maintains | Neutral |
| 04/24/2023 | — | Raymond James | Downgrades | Outperform → Market Perform | |
| 03/29/2023 | 195.57% | UBS | → $45 | Initiates Coverage On | → Neutral |
| 02/24/2023 | 208.7% | Raymond James | $52 → $47 | Maintains | Outperform |
| 02/23/2023 | 241.54% | Cowen & Co. | $61 → $52 | Maintains | Outperform |
| 02/23/2023 | 162.73% | Baird | $45 → $40 | Maintains | Neutral |
| 02/23/2023 | 228.41% | Piper Sandler | $70 → $50 | Maintains | Overweight |
| 01/26/2023 | — | Wolfe Research | Initiates Coverage On | → Peer Perform | |
| 11/15/2022 | 182.43% | Wells Fargo | → $43 | Upgrades | Underweight → Equal-Weight |
| 11/04/2022 | 241.54% | Raymond James | $92 → $52 | Maintains | Outperform |
| 11/03/2022 | 359.77% | Piper Sandler | $80 → $70 | Maintains | Overweight |
| 10/18/2022 | 392.61% | Barclays | → $75 | Initiates Coverage On | → Overweight |
| 10/12/2022 | 392.61% | Jefferies | → $75 | Initiates Coverage On | → Buy |
| 09/07/2022 | — | OTR Global | Downgrades | Positive → Mixed | |
| 08/09/2022 | 221.84% | Wells Fargo | $82 → $49 | Downgrades | Overweight → Underweight |
| 08/04/2022 | 491.13% | Raymond James | $125 → $90 | Maintains | Outperform |
| 08/04/2022 | 438.59% | Wells Fargo | $166 → $82 | Maintains | Overweight |
| 08/04/2022 | 425.45% | Piper Sandler | $120 → $80 | Maintains | Overweight |
| 05/17/2022 | 753.86% | Citigroup | $155 → $130 | Maintains | Buy |
| 05/05/2022 | 721.02% | Raymond James | $138 → $125 | Maintains | Outperform |
| 05/05/2022 | 688.18% | Piper Sandler | $170 → $120 | Maintains | Overweight |
| 05/05/2022 | 622.5% | SVB Leerink | $120 → $110 | Maintains | Market Perform |
| 02/23/2022 | 990.31% | Wells Fargo | $160 → $166 | Maintains | Overweight |
| 02/23/2022 | 918.06% | Citigroup | $163 → $155 | Maintains | Buy |
| 02/23/2022 | 688.18% | SVB Leerink | $140 → $120 | Maintains | Market Perform |
| 01/19/2022 | 950.9% | Wells Fargo | → $160 | Upgrades | Equal-Weight → Overweight |
| 11/04/2021 | 806.4% | Raymond James | $120 → $138 | Maintains | Outperform |
| 11/04/2021 | 819.54% | SVB Leerink | $135 → $140 | Maintains | Market Perform |
| 09/24/2021 | 786.7% | SVB Leerink | $123 → $135 | Maintains | Market Perform |
| 08/05/2021 | 688.18% | Raymond James | $115 → $120 | Maintains | Outperform |
| 08/05/2021 | 707.88% | SVB Leerink | $102 → $123 | Maintains | Market Perform |
| 05/25/2021 | 491.13% | Barclays | → $90 | Initiates Coverage On | → Underweight |
| 05/06/2021 | 569.95% | SVB Leerink | $95 → $102 | Maintains | Market Perform |
| 04/01/2021 | 523.97% | SVB Leerink | $115 → $95 | Maintains | Market Perform |
| 12/15/2020 | 589.66% | Wells Fargo | → $105 | Downgrades | Overweight → Equal-Weight |
| 11/06/2020 | 753.86% | SVB Leerink | $120 → $130 | Maintains | Market Perform |
| 11/06/2020 | 714.45% | Raymond James | $116 → $124 | Maintains | Outperform |
| 08/28/2020 | 688.18% | SVB Leerink | $115 → $120 | Maintains | Market Perform |
| 08/20/2020 | 688.18% | Wells Fargo | → $120 | Initiates Coverage On | → Overweight |
| 07/31/2020 | 661.9% | Raymond James | $95 → $116 | Maintains | Outperform |
| 07/31/2020 | 655.34% | SVB Leerink | $105 → $115 | Maintains | Market Perform |
| 07/06/2020 | 688.18% | Citigroup | $94 → $120 | Upgrades | Neutral → Buy |
| 06/22/2020 | 596.22% | UBS | $98 → $106 | Maintains | Buy |
| 06/18/2020 | 523.97% | Raymond James | $88 → $95 | Maintains | Outperform |
| 05/22/2020 | 523.97% | B of A Securities | $85 → $95 | Maintains | Neutral |
| 05/01/2020 | 432.02% | Citigroup | $74 → $81 | Maintains | Neutral |
| 05/01/2020 | 543.68% | UBS | $100 → $98 | Maintains | Buy |
| 05/01/2020 | 392.61% | Stifel | $65 → $75 | Maintains | Hold |
| 05/01/2020 | 478% | SVB Leerink | $85 → $88 | Maintains | Market Perform |
| 04/27/2020 | 432.02% | Raymond James | $91 → $81 | Maintains | Outperform |
| 04/24/2020 | — | SVB Leerink | Downgrades | Outperform → Market Perform | |
| 03/27/2020 | 386.04% | Citigroup | $89 → $74 | Maintains | Neutral |
| 02/25/2020 | 491.13% | Piper Sandler | $70 → $90 | Maintains | Overweight |
| 02/25/2020 | 405.75% | Stifel | $70 → $77 | Maintains | Hold |
| 02/25/2020 | 497.7% | Raymond James | $85 → $91 | Maintains | Outperform |
| 02/06/2020 | 458.29% | Raymond James | → $85 | Initiates Coverage On | → Outperform |
| 02/04/2020 | 392.61% | Baird | $71 → $75 | Downgrades | Outperform → Neutral |
| 11/05/2019 | 366.34% | Baird | $81 → $71 | Maintains | Outperform |
| 10/18/2019 | 399.18% | Guggenheim | → $76 | Initiates Coverage On | → Buy |
| 10/04/2019 | 392.61% | UBS | → $75 | Upgrades | Neutral → Buy |
| 05/13/2019 | 445.16% | SVB Leerink | → $83 | Initiates Coverage On | → Outperform |
| 05/01/2019 | 359.77% | Stifel | $58 → $70 | Maintains | Hold |
| 04/30/2019 | 333.5% | UBS | $53 → $66 | Maintains | Neutral |
| 03/08/2019 | 405.75% | BMO Capital | → $77 | Initiates Coverage On | → Outperform |
| 11/28/2018 | 136.45% | UBS | → $36 | Initiates Coverage On | → Neutral |
| 11/21/2018 | 202.13% | Baird | → $46 | Upgrades | Neutral → Outperform |
What is the target price for Tandem Diabetes Care (TNDM)?
The latest price target for Tandem Diabetes Care (NASDAQ: TNDM) was reported by Piper Sandler on November 2, 2023. The analyst firm set a price target for $25.00 expecting TNDM to rise to within 12 months (a possible 64.20% upside). 26 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Tandem Diabetes Care (TNDM)?
The latest analyst rating for Tandem Diabetes Care (NASDAQ: TNDM) was provided by Piper Sandler, and Tandem Diabetes Care maintained their overweight rating.
When is the next analyst rating going to be posted or updated for Tandem Diabetes Care (TNDM)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Tandem Diabetes Care, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Tandem Diabetes Care was filed on November 2, 2023 so you should expect the next rating to be made available sometime around November 2, 2024.
Is the Analyst Rating Tandem Diabetes Care (TNDM) correct?
While ratings are subjective and will change, the latest Tandem Diabetes Care (TNDM) rating was a maintained with a price target of $40.00 to $25.00. The current price Tandem Diabetes Care (TNDM) is trading at is $15.23, which is out of the analyst's predicted range.